MWNA
DRNA

Marshall Wace North America’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Marshall Wace North America’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$10.3M Buy
+511,674
New +$14.1M 0.04% 347
2021
Q1 		– Sell
-17,903
Closed -$394K – 1918
2020
Q4 		$394K Sell
17,903
-73,907
-80% -$1.63M ﹤0.01% 1130
2020
Q3 		$1.65M Buy
+91,810
New +$1.9M 0.01% 648
2020
Q2 		– Sell
-115,666
Closed -$2.13M – 1597
2020
Q1 		$2.13M Sell
115,666
-96,123
-45% -$1.87M 0.02% 468
2019
Q4 		$4.67M Buy
211,789
+211,274
+41,024% +$4.25M 0.02% 403
2019
Q3 		$8K Buy
+515
New +$7.36K ﹤0.01% 1268
2019
Q2 		– Sell
-17,886
Closed -$261K – 1787
2019
Q1 		$261K Buy
17,886
+12,939
+262% +$149K ﹤0.01% 924
2018
Q4 		$53K Buy
+4,947
New +$65.1K ﹤0.01% 1241

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $37.1M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return